Can Adcetris' narrow beat in new trial win a new FDA nod? Seattle Genetics, Takeda hope so
admin 26th June 2017 Uncategorised 0The good news for Seattle Genetics and Takeda: Their blood cancer drug Adcetris hit its primary goal in a Hodgkin lymphoma trial. The not-so-good news? Though Adcetris plus three chemo drugs together held off cancer progression, the combo didn’t perform dramatically better than a standard four-drug chemo regimen.
More: Can Adcetris' narrow beat in new trial win a new FDA nod? Seattle Genetics, Takeda hope so
Source: fierce